目的 探討潤肺膏聯(lián)合氨溴特羅口服溶液治療兒童支氣管炎的臨床療效。方法 選取石家莊市婦幼保健院在2021年2月—2024年1月收治的120例慢性支氣管炎急性發(fā)作期患兒，按隨機數(shù)字表法將所有患兒分為對照組和治療組，每組各60例。對照組口服氨溴特羅口服液，2～3歲7.5 mL/次，4～5歲10 mL/次，6～12歲15 mL/次，12歲以上20 mL/次，2次/d。治療組在對照組基礎(chǔ)上開水沖服潤肺膏，15 g/次，2次/d。兩組持續(xù)治療7 d。比較兩組的臨床療效、癥狀緩解時間、通氣功能指標(biāo)和血清炎癥指標(biāo)。結(jié)果 治療后，治療組的總有效率（95.00%）明顯高于對照組的總有效率（83.33%），差異有統(tǒng)計學(xué)意義（P＜0.05）。治療后，治療組患兒發(fā)熱、日間咳嗽、夜間咳嗽、喘息、肺啰音緩解時間均明顯短于對照組，差異有統(tǒng)計學(xué)意義（P＜0.05）。治療后，兩組的呼吸頻率（BF）、吸氣/呼氣時間比（TI/TE）低于治療前，潮氣量（VT）高于治療前（P＜0.05）；治療組的BF、TI/TE低于對照組，VT高于對照組（P＜0.05）。治療后，兩組的血清超敏C反應(yīng)蛋白（hs-CRP）、腫瘤壞死因子-α（TNF-α）水平低于治療前，血清甘露糖結(jié)合凝集素（MBL）水平高于治療前（P＜0.05）；治療組的血清hs-CRP、TNF-α水平低于對照組，血清MBL水平高于對照組（P＜0.05）。結(jié)論 潤肺膏聯(lián)合氨溴特羅口服溶液提高了兒童支氣管炎的臨床療效，改善了臨床癥狀和肺通氣功能，減輕了炎癥反應(yīng)。

Objective To investigate the clinical effect of Runfei Ointment combined with Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution in treatment of chronic bronchitis during acute stage in children. Methods Children (120 cases) with chronic bronchitis during acute stage admitted to Shijiazhuang Maternal and Child Health Hospital from February 2021 to January 2024 were selected. All children were divided into control and treatment group using a random number table method, with 60 cases in each group. In the control group, children took Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution, 7.5 mL/time at the age of 2 to 3, 10 mL/time at the age of 4 to 5, 15 mL/time at the age of 6 to 12, and 20 mL/time at the age of 12 and above, twice daily. On the basis of the control group, the children in the treatment group were po administered with Runfei Ointment with boiled water for 15 g/times, twice daily. Children in both groups were treated for 7 days. The clinical efficacy, the symptom relief time, ventilation function index, and serum inflammation index were compared between two groups. Results After treatment, the total effective rate of the treatment group (95.00%) was significantly higher than that of the control group (83.33%), and the difference was statistically significant (P < 0.05). After treatment, the remission time of fever, daytime cough, nighttime cough, wheezing, and pulmonary rales in the treatment group was significantly shorter than those in the control group, and the difference was statistically significant (P < 0.05). After treatment, BF and TI/TE of two groups were lower than those before treatment, but VT of two groups was higher than those before treatment (P < 0.05). BF and TI/TE in the treatment group were lower than those in the control group, but VT in the treatment group was higher than those in the control group (P < 0.05). After treatment, the serum levels of hs-CRP and TNF-α were lower than before treatment, but the serum levels of MBL were higher than before treatment (P < 0.05). The serum levels of hs-CRP and TNF-α in the treatment group were lower than those in the control group, but the serum levels of MBL in the treatment group were higher than those in the control group (P < 0.05). Conclusion Runfei Semifluid Extract combined with Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution can improve the clinical effect of pediatric bronchitis, improve the efficiency of symptom improvement, reduce inflammation and improve lung ventilation function.

R985

河北省中醫(yī)藥管理局科研計劃項目（2020287）